Intravenous ibandronate in men with osteoporosis: An open pilot study over 2 years

Journal of Endocrinological Investigation

Volumn 26, Issue 8, 2003, Pages 728-732

  Lamy, Olivier ^a   Sandini, L ^a   Pache, I ^a   Fatio, S ^a   Burnand, J ^a   Burckhardt, P ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Bisphosphonate; Bone mineral density; Ibandronate; Osteoporosis in men

Indexed keywords

1,25 HYDROXYVITAMIN D; 25 HYDROXYVITAMIN D; BETA CROSSLAP PROTEIN; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; IBANDRONIC ACID; OSTEOCALCIN; PARACETAMOL; PARATHYROID HORMONE; PROTEIN; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE;

ADULT; AGED; ARM FRACTURE; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE REMODELING; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHILIA; FEMUR; FEMUR NECK; FLU LIKE SYNDROME; HUMAN; INJECTION; LUMBAR SPINE; MALE; MONOCYTOSIS; NORMAL VALUE; OPEN STUDY; OSTEOPOROSIS; PILOT STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION; WRIST FRACTURE;

EID: 0344444353     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347354     Document Type: Article

References (16)

1. Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: A word-wide projection. Osteoporos Int 1992, 2: 285-9.
2. O'Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ. The prevalence of vertebral deformity in European men and women: The European Vertebral Osteoporosis Study. J Bone Miner Res 1996, 11: 1010-8.
3. Eastell R, Boyle IT, Compston J, et al. Management of male osteoporosis: Report of the UK Consensus Group. QJM 1998, 91: 71-92.
4. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000, 343: 604-10.
5. De Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D. Esophagitis associated with the use of alendronate. N Engl J Med 1996, 335: 1016-21.
6. Thiebaud D, Burckhardt P, Melchior J, et al. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int 1994, 4: 76-83.
7. Thiebaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997, 103: 298-307.
8. Ralston SH, Thiebaud D, Herrmann Z, et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 1997, 75: 295-300.
9. Riis BJ, Ise J, Von Stein T, Bagger Y, Christiansen C. Ibandronate: A comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001, 16: 1871-8.
10. Gluer CC, Blake G, Lu Y, Blunt BA, Jergas M, Genant HK. Accurate assessment of precision error: How to measure the reproducibility of bone densitometry techniques. Osteoporos Int 1995, 4: 262-70.
11. Garnero P, Grimaux M, Demiaux B, Delmas PD. Measurement of serum osteocalcin with a human specific two-site radioimmunoassay. J Bone Miner Res 1992, 7: 1389-97.
12. Kaufmann Didisheim N. Définition de l'intervalle de référence de la calcémie dans une population hospitalière. Doctor's thesis, Faculty of medicine, University of Lausanne, Switzerland, 1989.
13. Pols HAP, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomised trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Osteoporos Int 1997, 9: 461-8.
14. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomised controlled trial. JAMA 1999, 282: 1344-52.
15. Ravn P, Neugebauer G, Christiansen C. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone 2002, 30: 320-4.
16. Adami S, Delmas P, Felsenberg D, et al. Three-monthly 2 mg intravenous ibandronate bolus injections significantly increase BMD in women with postmenopausal osteoporosis. IOF World Congress of Osteoporosis, Lisbon, Portugal, 2002, p S14-5 (abstract).